Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.
about
The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin.Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.The role of astrocytes in CNS tumors: pre-clinical models and novel imaging approachesA machine learned classifier that uses gene expression data to accurately predict estrogen receptor statusPRMT2 and RORĪ³ expression are associated with breast cancer survival outcomes.Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition?Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways.Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Metastatic progression of breast cancer: insights from 50 years of autopsies.Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypesRetrospective analysis of metastatic behaviour of breast cancer subtypesEfficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.Triple-Negative Breast Cancer: Clinical and Histological Correlations.An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsBreaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies.c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression.Organ-specific adaptive signaling pathway activation in metastatic breast cancer cellsPhosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis.NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple MetastasesA model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis.Breast carcinoma subtypes show different patterns of metastatic behavior.P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma.Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy.Bridging cancer biology with the clinic: relative expression of a GRHL2-mediated gene-set pair predicts breast cancer metastasis.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
P2860
Q27317001-7644A52F-2141-4814-902A-4B89BA5DE678Q30238959-B15E7D1B-6D00-4B9F-B7B0-ED74C9062A8EQ30618244-382EE75A-36E9-4677-90F6-B562A61343EBQ30710027-FE92A391-D7E5-4CD1-87A8-2607F7726D90Q33632034-EABA558D-7930-425E-86FF-C7BFF11204C6Q33738679-7C6407D3-DC19-4C51-AEA7-C6046AFC2333Q33742688-44C56B9D-3DB4-4D2A-961F-F31731787B10Q33887682-6DBFF7CF-C1EE-441C-A649-DE325B82D78CQ33891408-51757826-F209-49E7-A3FA-40B9AC4691BAQ33916814-D7FF31E7-B6BA-4B45-B4A2-6D71A93762DEQ33917567-4366264F-AD62-49E0-B405-3267DF32C103Q34168896-B0C02149-8B5D-4EC0-AE14-5451C6430673Q34708283-058D4605-5787-4AC0-9E2F-5FCA8F6F51B4Q34891023-AA5A7C75-4123-4EB9-8EE8-C885CC01B6FFQ35000353-5CCBAB07-74CA-4830-AB09-D5D560BF4A72Q35020412-7A4914A2-16C2-42DA-9A19-87168F90E5B8Q35079683-353CDB3F-79AF-4F93-8857-AACDAC0FB99BQ35143022-DE88A8EB-0247-49F4-AD9E-705592E9C4DBQ35149532-082066EE-C57F-4275-A2B7-1F6731F66E4DQ35252752-20B9ED1B-43BC-4A1C-82E8-053B2CF16FB9Q35374807-6F84050D-E3EB-45B3-82F0-E32F6CA9953CQ35551911-D083C92E-07FB-4C70-8EBF-2F5376B4AEACQ35576252-34D15751-3145-4B5D-B996-85ACD7641D57Q35611844-F0748BD9-92CD-4AF8-896E-1D76BF7EB875Q35651216-FD51DFBA-A906-4515-AF30-D18BE080B6FEQ35786301-A18D2745-D8B9-4931-BF7D-D1B69B575F17Q35828457-CD7C9084-D854-4B61-9802-81C84FA29D5BQ35828652-AB122A36-A246-43E4-9F50-A6A0ADC9C855Q35889638-9579AF22-A8ED-4A82-8AAF-6256A5D5D9B9Q35892362-3A9D3088-28C9-4190-9E9E-576B830E23B8Q35980816-CD2BBB97-CEDD-4138-8103-ABDCD7315D5CQ36143238-A7B55FAE-BA2A-4127-984A-8C11E7D3AF6FQ36214193-3813387A-C810-4A27-80A5-DF80001F854DQ36251962-CC177C20-C416-4F1C-85F7-F0FF9DDED56BQ36253544-D4828993-9745-4F10-A40B-7D473BA962A7Q36289931-C695E693-71D7-4645-A27D-6E15A0C7324EQ36321648-39D0A472-A585-4AC7-A7B4-CE391C5319B4Q36397832-668CE6FE-0036-4F09-BBB9-BC1EB1CAB664Q36618503-D81E6B7B-BDDE-4F2F-8567-59F3A031A618Q36630430-AF60CE99-73B0-4F2E-A96D-44FD8541220E
P2860
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.
description
2011 nĆ® lÅ«n-bĆ»n
@nan
2011 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2011 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2011幓ć®č«ę
@ja
2011幓č«ę
@yue
2011幓č«ę
@zh-hant
2011幓č«ę
@zh-hk
2011幓č«ę
@zh-mo
2011幓č«ę
@zh-tw
2011幓č®ŗę
@wuu
name
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@ast
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@en
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@nl
type
label
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@ast
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@en
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@nl
prefLabel
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@ast
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@en
Genomic analysis identifies un ...... rain, lung, and liver relapse.
@nl
P2093
P2860
P50
P1476
Genomic analysis identifies un ...... brain, lung, and liver relapse
@en
P2093
Carey Anders
Joel S Parker
Lisa Carey
Matthew Ewend
Xiaping He
P2860
P2888
P304
P356
10.1007/S10549-011-1619-7
P407
P577
2011-06-14T00:00:00Z
P5875
P6179
1051170071